European Journal of Medicinal Chemistry p. 438 - 457 (2017)
Update date:2022-08-17
Topics:
Brogi, Simone
Ramunno, Anna
Savi, Lida
Chemi, Giulia
Alfano, Gloria
Pecorelli, Alessandra
Pambianchi, Erika
Galatello, Paola
Compagnoni, Giulia
Focher, Federico
Biamonti, Giuseppe
Valacchi, Giuseppe
Butini, Stefania
Gemma, Sandra
Campiani, Giuseppe
Brindisi, Margherita
The manuscript deals with the design, synthesis and biological evaluation of novel benzoxazinone-based and indole-based compounds as multifunctional neuroprotective agents. These compounds inhibit human adenosine kinase (hAK) and human glycogen synthase kinase 3 beta (hGSK-3β) enzymes. Computational analysis based on a molecular docking approach underlined the potential structural requirements for simultaneously targeting both proteins’ allosteric sites. In silico hints drove the synthesis of appropriately decorated benzoxazinones and indoles (5a-s, and 6a-c) and biochemical analysis revealed their behavior as allosteric inhibitors of hGSK-3β. For both our hit 4 and the best compounds of the series (5c,l and 6b) the potential antioxidant profile was assessed in human neuroblastoma cell lines (IMR 32, undifferentiated and neuronal differentiated), by evaluating the protective effect of selected compounds against H2O2 cytotoxicity and reactive oxygen species (ROS) production. Results showed a strong efficacy of the tested compounds, even at the lower doses, in counteracting the induced oxidative stress (50 μM of H2O2) and in preventing ROS formation. In addition, the tested compounds did not show any cytotoxic effect determined by the LDH release, at the concentration range analyzed (from 0.1 to 50 μM). This study allowed the identification of compound 5l, as the first dual hAK/hGSK-3β inhibitor reported to date. Compound 5l, which behaves as an effective antioxidant, holds promise for the development of new series of potential therapeutic agents for the treatment of neurodegenerative diseases characterized by an innovative pharmacological profile.
View MoreCHANGYI CITY FENGRUN FINE CHEMICAL CO.,LTD
website:http://www.fengrunhuagong.com
Contact:+86-536-7869976
Address:Changyi Coastal Economic Development Zone
Shanghai Dano Pharmaceutical Co.,Ld.(expird)
Contact:+86-592-6266840
Address:Building 1 Room 512, 720 Cailun Rd, Zhangjiang High-Tech Park, Shanghai 201203, China
Luojiang Chenming Biological Products Co
Contact:+86 15000297032
Address:GROUP NO.4, HE SHENG VILLAGE, PANLONG TOWN,
Shanggao Ruiya Fine Chemicals Co., Ltd
Contact:+86-795-2592103
Address:Xingguang Nanlu,Shanggao County Industry Park
FOSHAN NANHAI ZHONGNAN PHARMACEUTICAL FACTORY
Contact:0086-0757-85609331
Address:XIAHENGTIAN INDUSTRIAL ZONE,SHAYONG VILLAGE,LISHUI TOWN
Doi:10.1016/0040-4020(72)84008-0
(1972)Doi:10.1016/j.inoche.2016.01.011
(2016)Doi:10.1002/ejic.201801501
(2019)Doi:10.1016/j.cclet.2021.01.024
(2021)Doi:10.1002/jccs.201600192
(2017)Doi:10.1021/ic50041a032
(1966)